Boston Scientific Corporation cash flow to debt ratio of 36.51% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Boston Scientific Corporation's free cash flow has increased 38.30% from $2.65B last year to $3.66B, signaling increasing performance

Boston Scientific Corporation's debt to equity ratio is 0.51, which means that the company's assets are healthy financed, signaling financial stability.

Boston Scientific Corporation's debt has decreased relative to shareholder equity from 0.51 last year to 0.51 today, signaling strengthened financials

Boston Scientific Corporation has a net debt to EBITDA ratio of 2.03x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Boston Scientific Corporation's interest coverage ratio of 12.41 indicates that earnings with good margin can cover interest payments on company debt

Boston Scientific Corporation's profit margin has increased (57.76%) in the last year from 11.07% to 17.47%, signaling increasing performance

Boston Scientific Corporation's short-term assets of $8.79B exceed its short-term liabilities of $5.44B

Boston Scientific Corporation's return on assets of 8.11% is higher than the 5.00% threshold, indicating efficient asset utilization

Boston Scientific Corporation's return on equity of 14.90%, is lower than 15.00%, indicating bad performance

Boston Scientific Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Boston Scientific Corporation had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Boston Scientific Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Boston Scientific Corporation has a free cash flow yield of 4.88%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Boston Scientific Corporation's yearly earnings has increased 55.66% since last year from $1.85B to $2.89B, signaling increasing performance

Boston Scientific Corporation's yearly revenue has increased 19.87% since last year from $16.75B to $20.07B, signaling increasing performance

ROIC 10.57% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Boston Scientific Corporation's 3-year revenue CAGR of 16.54% is positive, indicating growing revenue over the past 3 years

Boston Scientific Corporation had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Boston Scientific Corporation had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Boston Scientific Corporation is overvalued relative to its fair value price of 36.71 based on Discounted Cash Flow model

Boston Scientific Corporation has an earnings yield of 4.92%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Boston Scientific Corporation is overvalued relative to its fair value price of 10.61 based on EBITDA multiple model

Boston Scientific Corporation has an EV/EBITDA ratio of 16.73x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Boston Scientific Corporation is overvalued relative to its fair value price of 43.21 based on Earnings Fair Value model

Boston Scientific Corporation had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Boston Scientific Corporation has a price-to-book ratio of 2.96x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Boston Scientific Corporation has a price-to-sales ratio of 3.55x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue